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Background
The ability to elicit broadly cross-reactive neutralizing
antibodies is a major challenge in the development of an
HIV-1 vaccine capable of neutralizing broad array of
viruses in circulation. Nevertheless, a number of HIV-1
infected donors have broadly neutralizing sera and a
handful of broadly neutralizing monoclonal antibodies
have been isolated from clade B infected donors arguing
that a vaccine strategy based upon eliciting broadly pro-
tective antibodies is feasible. These antibodies tend to dis-
play less breadth and potency against non-clade B viruses
and they recognize epitopes on the virus that have so far
proven refractory to incorporation into immunogens for
elicitation of virus neutralizing responses.
Methods
Following a large-scale systematic evaluation of neutraliz-
ing breadth in the sera of about 1,800 HIV-1 donors,
mostly infected with non-clade B viruses, we have begun
to generate monoclonal antibodies from these donors.
Using a sensitive high-throughput micro-neutralization
screening of supernatants from approximately 30,300
memory B cells from a HIV-1 non-clade B infected donor,
we idenified two new broad neutralizing monoclonal
antibodies.
Results
We isolated two potent broadly cross-clade neutralizing
monoclonal antibodies, PG9 and PG16, that target an
epitope not previously described. For both PG9 and
PG16, the epitope is preferentially expressed on trimeric
envelope, either on transfected/infected cell surfaces or on
the HIV-1 virion, although weak binding to soluble mon-
omeric gp120 or trimeric gp140 is observed for PG9. Pre-
liminary epitope mapping studies suggests, PG9 and
PG16 bind to conserved regions of variable loops on
gp120 in the HIV-1 envelope trimer. Further studies to
precisely map the epitope are in progress.
Conclusion
The ability of the newly identified antibodies to neutralize
primary viruses isolates from different clades with unprec-
edented potency, their preference for native HIV-1 trimers
and the accessibility of their epitope, will likely make
them valuable tools for HIV-1 vaccine design.
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